#Italy #Rome #Biomedical Innovations #Haier Biomedical #European Summit

Haier Biomedical's European Partner Summit in Rome

Haier Biomedical recently held its European partner summit in Rome under the theme of "Advancing Together – Sharing the Future of Biomedical Innovations," gathering 37 regional partners and industry leaders from 23 European countries. This event marked a pivotal moment in the company’s commitment to a long-term vision for Europe, showcasing an expanded laboratory solutions portfolio as part of its strategic brand modernization.

Long-Term Commitment to Europe

The summit was designed not only to outline the company’s dedication to European operations but also to share its updated strategy aimed at enhancing localization within Europe. This strategy emphasizes scenario-based applications and comprehensive service delivery tailored to the unique regulatory environment, customer expectations, and application needs in various European markets.

Enrique Wang, the Global Market Director at Haier Biomedical, shared ambitious goals that include achieving over 50% of global revenues from international markets by 2027. He highlighted that Europe is a strategic priority within this globalization plan, underscoring the principle of "In Europe, for Europe." This principle revolves around delivering products and support specifically aligned with regional needs and standards.

European Market Dynamics

Semir Selimovic, the Director for Northern, Central, and Eastern Europe at Haier Biomedical Europe, explained the strategy designed for the European market through 2026. He stressed ongoing investments in local sales, services, and product expertise, which are crucial for effectively responding to key market demands. Notably, Europe has become one of Haier Biomedical’s fastest-growing international regions, prompting the expansion of local teams and a continuously evolving product portfolio.

Innovative Product Showcase

Among the new products featured, the plasma apheresis system XJ-III caught attention, having received EU MDR certification, a significant achievement in meeting stringent European regulatory standards. Haier Biomedical's CO₂ incubators, centrifuges, bio-safety cabinets, and cold-chain solutions are increasingly capturing market share, thanks to energy-efficient technologies and compliance with regional certification norms.

The showcased products were part of a broader narrative towards releasing a comprehensive portfolio to support laboratories, hospitals, and life sciences institutions with all-inclusive solutions.

Automation and Smart Blood Processing as Growth Drivers

Daniele Pericolini, a specialist in European automation solutions at Haier Biomedical, elaborated on the company's future growth strategy, focusing on laboratory automation and smart blood processing systems. Their automated biobank solutions integrate ultra-low temperature storage with RFID support, modular automation platforms, and liquid nitrogen systems to enhance sample traceability and operational efficiency. By addressing challenges such as sample integrity and temperature monitoring, Haier Biomedical positions itself within the growing European infrastructure demand for advanced biobanking.

The intelligent blood processing system U-Blood signifies a shift from traditional cold storage towards a connected real-time blood supply chain management approach. This innovation aligns with Europe’s increased focus on safety, digitalization, and zero-waste healthcare initiatives.

Local Success Stories

The summit also spotlighted success stories from four European partners representing Germany, Slovenia, France, and Denmark, highlighting the strong local recognition of Haier Biomedical’s solutions. In France, a long-term partner introduced a jointly developed bio-safety cabinet that met French standards, with over 230 units deployed across more than 100 customers. Meanwhile, a partner in Denmark shared insights into their procurement successes delivering ultra-low temperature freezers while expanding into additional product categories. Extensive pharmaceutical installations in Slovenia showcased the company’s capabilities in managing complex multi-unit projects, with Central European partners emphasizing reliability and post-sales support as key differentiators.

Strong International Growth in 2025

The expanding European footprint has been backed by robust financial results. In 2025, Haier Biomedical reported revenues exceeding 2.3 billion RMB, with international sales reaching 840 million RMB, representing over 36% of total revenue—a clear indicator of ongoing global expansion. Europe recorded double-digit growth, significantly contributing to the overall increase in international sales, with AI and automation-supported solutions accounting for approximately 15% of total revenue.

This shift illustrates a broader transition from hardware exportation to localized solution delivery backed by regional teams and certifications across more than 18 countries.

At the conclusion of the European partners summit, Haier Biomedical reiterated its commitment to strengthen localized operations, expand automation, and support life sciences solutions contributing to shared growth among partners. By combining global innovative capabilities with local execution in Europe, the company aims to solidify its position as a trusted provider of life sciences solutions well into 2026 and beyond.